Immune-Mediated Hemolytic Anemia in Dogs: Welfare Management

IMHA is a life-threatening autoimmune condition in dogs requiring intensive care, careful monitoring, and long-term immunosuppression management.

Key Facts

IMHA occurs when the immune system destroys the dog's own red blood cells
It is one of the most common immune-mediated diseases in dogs
Cocker Spaniels, Irish Setters, and Poodles are among predisposed breeds
Signs include pale gums, lethargy, yellow tinge to skin/eyes (jaundice), and collapse
Treatment includes immunosuppressive drugs (prednisone), blood transfusions, and antithrombotic therapy
Thromboembolism is a major complication causing high mortality even with treatment
Relapse occurs in 10-15% of cases; some dogs require lifelong low-dose immunosuppression

Welfare Considerations

IMHA causes rapid, severe deterioration - anemia produces profound weakness, and the disease course is frightening for both patient and owner. Intensive veterinary care involving multiple medications, monitoring, and possible transfusions is often required. Long-term immunosuppression carries its own welfare costs including increased infection risk and drug side effects. Careful tapering of medications and monitoring for relapse are essential to long-term welfare management.

What You Can Do

Seek emergency veterinary care immediately if your dog shows pale gums or sudden collapse
Follow immunosuppressive tapering schedules exactly as directed - stopping early risks relapse
Monitor for infection signs during immunosuppression treatment
Schedule regular blood counts to track red blood cell recovery and guide medication adjustment
Discuss relapse risk and long-term management plan with your veterinarian